Abstract:There are presented the immediate and long-term results of neoadjuvant endocrine therapy versus chemotherapy in ER+ breast cancer and chemotherapy (carboplatin + taxane) at triple-negative tumor subtype. We marked a tendency of improving a 10-year disease-free survival at luminal A subtype in patients who received endocrine therapy compared with chemotherapy (72.8% vs. 53.9%; p=0.062). Only 5.9% of patients with ER+ /HER2+ co-expression, who received target therapy, reached complete regression (pCR). There was… Show more
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.